History & Milestones
- 2025
Established BioPhoenix Co.
March 12, 2025: BioPhoenix Co. was formally established as a spin-off from the New Drug Development Division of San Fu Biotech, a subsidiary of San Fu Chemical Co.
March 26, 2025: Submitted a PCT patent application for BPC2002, a new indication for the treatment of psoriasis.
April 24, 2025: Submitted an IND application for a Phase 2b clinical trial of BPC2001, a novel therapy for the prevention of acute graft-versus-host disease (GvHD), to the China National Medical Products Administration (NMPA); the application was officially accepted for review.
June 16, 2025: Signed a global licensing Binding Term Sheet with Up Therapeutics, a Johns Hopkins School of Medicine spin-out, to in-license Up284, a first-in-class therapy for ovarian cancer.